- $50.05bn
- $30.07bn
- $77.08bn
- 67
- 90
- 59
- 84
Annual cashflow statement for Metlife, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | 10-K | 10-K | 10-K | 10-K | |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | 6,876 | 5,302 | 1,602 | 4,444 | — |
| Depreciation | |||||
| Non-Cash Items | -1,960 | -685 | 3,697 | 3,565 | — |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6,737 | 7,754 | 7,704 | 5,875 | — |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Gains / Losses on Investment Securities | |||||
| Change in Deferred Policy Acquisition Costs | |||||
| Change in Reinsurance Receivable | |||||
| Change in Insurance Reserves | |||||
| Cash from Operating Activities | 12,347 | 13,044 | 13,721 | 14,598 | — |
| Other Investing Cash Flow Items | -11,187 | -2,620 | -10,246 | -11,493 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Policy Loans | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11,187 | -2,620 | -10,246 | -11,493 | — |
| Financing Cash Flow Items | 4,268 | 5,013 | 4,498 | 3,029 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,126 | -9,948 | -2,940 | -3,131 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -444 | 79 | 444 | -571 | — |